Search

Your search keyword '"Heinke, Sophie"' showing total 6 results
Start Over Author "Heinke, Sophie"
6 results on '"Heinke, Sophie"'

1. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes

Author

Ludwig, Barbara, Ludwig, Stefan, Steffen, Anja, Knauf, Yvonne, Zimerman, Baruch, Heinke, Sophie, Lehmann, Susann, Schubert, Undine, Schmid, Janine, Bleyer, Martina, Schönmann, Uwe, Colton, Clark K., Bonifacio, Ezio, Solimena, Michele, Reichel, Andreas, Schally, Andrew V., Rotem, Avi, Barkai, Uriel, Grinberg-Rashi, Helena, Kaup, Franz-Josef, Avni, Yuval, Jones, Peter, and Bornstein, Stefan R.

Published
2017

3. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes

Author

Massachusetts Institute of Technology. Department of Chemical Engineering, Colton, Clark K, Ludwig, Barbara, Ludwig, Stefan, Steffen, Anja, Knauf, Yvonne, Zimerman, Baruch, Heinke, Sophie, Lehmann, Susann, Schubert, Undine, Schmid, Janine, Bleyer, Martina, Schönmann, Uwe, Bonifacio, Ezio, Solimena, Michele, Reichel, Andreas, Schally, Andrew V., Rotem, Avi, Barkai, Uriel, Grinberg-Rashi, Helena, Kaup, Franz-Josef, Avni, Yuval, Jones, Peter, Bornstein, Stefan R., Massachusetts Institute of Technology. Department of Chemical Engineering, Colton, Clark K, Ludwig, Barbara, Ludwig, Stefan, Steffen, Anja, Knauf, Yvonne, Zimerman, Baruch, Heinke, Sophie, Lehmann, Susann, Schubert, Undine, Schmid, Janine, Bleyer, Martina, Schönmann, Uwe, Bonifacio, Ezio, Solimena, Michele, Reichel, Andreas, Schally, Andrew V., Rotem, Avi, Barkai, Uriel, Grinberg-Rashi, Helena, Kaup, Franz-Josef, Avni, Yuval, Jones, Peter, and Bornstein, Stefan R.

Abstract

Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencap-sulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions. Keywords: diabetes; porcine islets; beta-cell replacement; immune barrier

Published
2018

6. Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony.

Author

Hommel, Angela, Haupt, Florian, Delivani, Petrina, Winkler, Christiane, Stopsack, Marina, Wimberger, Pauline, Nitzsche, Katharina, Heinke, Sophie, Naeke, Andrea, Ceglarek, Uta, Thiery, Joachim, Bergert, Renate, Stadthaus, Daniel, Groeger, Katrin, Heubner, Georg, Schramm, Ursula, Dziambor, Ullrich, Zirkel, Agnes, Kiess, Wieland, and Mueller, Iris

Subjects
DIABETES, TYPE 1 diabetes, NEWBORN screening, PILOT projects, DIAGNOSIS, IMMUNOLOGY, DIABETES risk factors
Abstract

An increased risk for type 1 diabetes can be identified using genetic and immune markers. The Freder1k study introduces genetic testing for type 1 diabetes risk within the context of the newborn screening in order to identify newborns with a high risk to develop type 1 diabetes for follow-up testing of early stage type 1 diabetes and for primary prevention trials. Consent for research-based genetic testing of type 1 diabetes risk is obtained with newborn screening. Increased risk is assessed using three single nucleotide polymorphisms for HLA DRB1*03 (DR3), HLA DRB1*04 (DR4), HLA DQB1*0302 (DQ8) alleles, and defined as 1. an HLA DR3/DR4-DQ8 or DR4-DQ8/DR4-DQ8 genotype or 2. an HLA DR4-DQ8 haplotype and a first-degree family history of type 1 diabetes. Families of infants with increased risk are asked to participate in follow-up visits at infant age 6 months, 2 years, and 4 years for autoantibody testing and early diagnosis of type 1 diabetes. After 8 months, the screening rate has reached 181 per week, with 63% coverage of newborns within Freder1k-clinics and 24% of all registered births in Saxony. Of 4178 screened, 2.6% were identified to have an increased risk, and around 80% of eligible infants were recruited to follow-up. Psychological assessment of eligible families is ongoing with none of 31 families demonstrating signs of excessive burden associated with knowledge of type 1 diabetes risk. This pilot study has shown that it is feasible to perform genetic risk testing for childhood disease within the context of newborn screening programs. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results